Bitterroot Bio
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3160 Porter Dr Ste 220, Palo Alto, Calif...Website
www.brbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Bitterroot Bio
Based out of Palo Alto, Bitterroot Bio, is a biotechnology company with a focus on novel immunotherapies in cardiovascular disease.Explore more
Bitterroot Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bitterroot Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Bitterroot Bio launches new products
Congratulate Masked Content for being promoted to Masked Content at Bitterroot Bio
Check out if Bitterroot Bio is spiking on competitors!
Funding: Get notified immidiatlly once Bitterroot Bio has new funding data
Bitterroot Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Bitterroot Bio had a recent Job posting/layoffs
Check if Bitterroot Bio has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Bitterroot Bio recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Bitterroot Bio
Find 3 more new buyers
Company Profile Activity
Activity Insights
Bitterroot Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Bitterroot Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Bitterroot Bio.
Bitterroot Bio financials insights
Gather financial insights about Bitterroot Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$145M
Bitterroot Bio Tech Stack
A closer look at the technologies used by Bitterroot Bio
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Executive Move
Executive Moves, Board of Directors
Facilities Relocation / Expansion
Bitterroot Bio is planning to move offices in March 2025. The move will impact approximately 15 employees at the existing office located at 3160 Porter Dr, Suite #220, Palo Alto, CA.
Facilities Relocation/Expansion
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Bitterroot Bio News & Media
Bitterroot Bio Announces Dosing of First Patient in MATADOR Phase 2a Study of BRB-002, an Immunomodulating Therapy Targeting CD47 in Atherosclerotic Cardiovascular Disease
-Dosing initiated in proof-of-concept MATADOR Phase 2a study-Bitterroot Bio to Present Detailed Results from Phase 1 Study of BRB-002 at American College of Cardiology Annual Scientific Session 2025
PALO ALTO, Calif. and NEEDHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, announced today that the Company will present results from the Phase 1 study of BRB-002 in healthy volunteers at the American College of Cardiology (ACC) Annual Scientific Session 2025, taking place in Chicago, Illinois, March 29 – 31, 2025.Bitterroot Bio Reports Data on Safety and Target Engagement from Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers
PALO ALTO, Calif. and NEEDHAM, Mass. and MELBOURNE, Australia, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced positive results from a recently completed Phase 1 study of BRB-002 in healthy volunteers. BRB-002 is a first-in-class, immune modulating protein therapy that targets CD47 for treatment of atherosclerotic cardiovascular disease.Bitterroot Bio Completes Enrollment in Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers
PALO ALTO, Calif. and NEEDHAM, Mass. and MELBOURNE, Australia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced the completion of enrollment in its Phase 1 study evaluating BRB-002 in healthy volunteers.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Bitterroot Bio
Sign Up For FreeTo access detailed company insights
Based out of Palo Alto, Bitterroot Bio, is a biotechnology company with a focus on novel immunotherapies in cardiovascular disease.... Read More
